Clinical Development

BD acquires Atto Bioscience

BD acquires Atto Bioscience

BD Biosciences has acquired Atto Bioscience in a deal worth $25
million (€20m), allowing it to enter the emerging high content cell
analysis market and enhancing its presence in the pharmaceutical
and biotechnology sectors.

Follow us

Featured Events

View more

Products

View more

Webinars